CAREDX, INC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 7.56 USD | 0.00% |
|
-9.03% | -37.00% |
| 04-16 | CareDx Appoints John Hanna as CEO, President | MT |
| 04-16 | CareDx, Inc Appoints John W. Hanna as Chief Executive Officer | CI |
| Sales 2024 * | 267M 365M | Sales 2025 * | 287M 392M | Capitalization | 391M 535M |
|---|---|---|---|---|---|
| Net income 2024 * | -80M -109M | Net income 2025 * | -64M -87.48M | EV / Sales 2024 * | 1.37 x |
| Net cash position 2024 * | 24.45M 33.42M | Net Debt 2025 * | 1.1M 1.51M | EV / Sales 2025 * | 1.37 x |
| P/E ratio 2024 * |
-5.02
x | P/E ratio 2025 * |
-6.42
x | Employees | 639 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 96.25% |
More Fundamentals
* Assessed data
More news
Latest transcript on CareDx, Inc
More recommendations
More press releases
More news
| 1 week | -9.03% | ||
| Current month | -28.61% | ||
| 1 month | -21.00% | ||
| 3 months | -16.19% | ||
| 6 months | +50.00% | ||
| Current year | -37.00% |
1 week
7.42
8.76
1 month
7.4211.10
Current year
7.4212.83
1 year
4.8012.93
3 years
4.8096.88
5 years
4.8099.83
10 years
0.7699.83
| Managers | Title | Age | Since |
|---|---|---|---|
Abhishek Jain
DFI | Director of Finance/CFO | 48 | 21-07-31 |
Ashish Kothari
CTO | Chief Tech/Sci/R&D Officer | - | - |
Marica Grskovic
COO | Chief Operating Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 15-03-01 | |
| Director/Board Member | 68 | 14-04-07 | |
| Director/Board Member | 72 | 19-08-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.15% | 1 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 7.56 | 0.00% | 492,984 |
| 24-04-25 | 7.56 | -5.26% | 555,486 |
| 24-04-24 | 7.98 | -3.04% | 757,592 |
| 24-04-23 | 8.23 | +0.73% | 448,610 |
| 24-04-22 | 8.17 | -1.68% | 480,802 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
CareDx, Inc. is a precision medicine solutions company. The Company is focused on the discovery, development, and commercialization of clinically differentiated, diagnostic solutions for transplant patients and caregivers. The Company offers testing services, products, and patient and digital solutions along the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. Its commercially available testing services consist of AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The Companyâs product portfolio includes AlloSeq Tx, QTYPE, Olerup SSP, AlloSeq HCT and AlloSeq cfDNA. It develops and provides diagnostic surveillance testing services for various transplant recipients.
Calendar
2024-05-01
- Q1 2024 Earnings Release (Projected)
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
C-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
7.56
USD
Average target price
12.5
USD
Spread / Average Target
+65.34%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -37.00% | 391M | |
| -20.45% | 10.82B | |
| +43.17% | 3.25B | |
| -35.86% | 2.11B | |
| -17.21% | 2.08B | |
| -29.81% | 1.48B | |
| +17.56% | 1.02B | |
| -4.37% | 733M | |
| -46.94% | 377M | |
| +13.32% | 332M |
- Stock Market
- Equities
- CDNA Stock
